BioLASCO Taiwan Co., Ltd. (TPEX:6662)

Market Cap	779.89M
Revenue (ttm)	277.12M
Net Income (ttm)	44.74M
Shares Out	25.61M
EPS (ttm)	1.75
PE Ratio	17.43
Forward PE	n/a
Dividend	1.50 (4.91%)
Ex-Dividend Date	Aug 7, 2025

Volume	33,882
Average Volume	13,223
Open	30.30
Previous Close	30.45
Day's Range	29.95 - 30.30
52-Week Range	29.95 - 36.70
Beta	0.19
RSI	45.82
Earnings Date	Mar 20, 2026

About BioLASCO Taiwan

BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine di...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 91
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6662

Financial Performance

In 2024, BioLASCO Taiwan's revenue was 292.50 million, an increase of 10.49% compared to the previous year's 264.72 million. Earnings were 44.03 million, a decrease of -11.49%.